Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa, Roberta, Damiano, Vincenzo, Formisano, Luigi, Nappi, Lucia, Marciano, Roberta, Veneziani, Bianca Maria, De Placido, Sabino, Bianco, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782521/
https://www.ncbi.nlm.nih.gov/pubmed/24083076
http://dx.doi.org/10.4161/onci.25123
_version_ 1782285568904790016
author Rosa, Roberta
Damiano, Vincenzo
Formisano, Luigi
Nappi, Lucia
Marciano, Roberta
Veneziani, Bianca Maria
De Placido, Sabino
Bianco, Roberto
author_facet Rosa, Roberta
Damiano, Vincenzo
Formisano, Luigi
Nappi, Lucia
Marciano, Roberta
Veneziani, Bianca Maria
De Placido, Sabino
Bianco, Roberto
author_sort Rosa, Roberta
collection PubMed
description The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials investigating the combination of mTOR inhibitors with TLR9 agonists in RCC patients have been performed to date. Our results may pave the way to translate this combinatorial approach to the clinical setting.
format Online
Article
Text
id pubmed-3782521
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-37825212013-09-30 Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma Rosa, Roberta Damiano, Vincenzo Formisano, Luigi Nappi, Lucia Marciano, Roberta Veneziani, Bianca Maria De Placido, Sabino Bianco, Roberto Oncoimmunology Author's View The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials investigating the combination of mTOR inhibitors with TLR9 agonists in RCC patients have been performed to date. Our results may pave the way to translate this combinatorial approach to the clinical setting. Landes Bioscience 2013-08-01 2013-05-28 /pmc/articles/PMC3782521/ /pubmed/24083076 http://dx.doi.org/10.4161/onci.25123 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Rosa, Roberta
Damiano, Vincenzo
Formisano, Luigi
Nappi, Lucia
Marciano, Roberta
Veneziani, Bianca Maria
De Placido, Sabino
Bianco, Roberto
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
title Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
title_full Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
title_fullStr Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
title_full_unstemmed Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
title_short Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
title_sort combination of a toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782521/
https://www.ncbi.nlm.nih.gov/pubmed/24083076
http://dx.doi.org/10.4161/onci.25123
work_keys_str_mv AT rosaroberta combinationofatolllikereceptor9agonistwitheverolimusinterfereswiththegrowthandangiogenicactivityofrenalcellcarcinoma
AT damianovincenzo combinationofatolllikereceptor9agonistwitheverolimusinterfereswiththegrowthandangiogenicactivityofrenalcellcarcinoma
AT formisanoluigi combinationofatolllikereceptor9agonistwitheverolimusinterfereswiththegrowthandangiogenicactivityofrenalcellcarcinoma
AT nappilucia combinationofatolllikereceptor9agonistwitheverolimusinterfereswiththegrowthandangiogenicactivityofrenalcellcarcinoma
AT marcianoroberta combinationofatolllikereceptor9agonistwitheverolimusinterfereswiththegrowthandangiogenicactivityofrenalcellcarcinoma
AT venezianibiancamaria combinationofatolllikereceptor9agonistwitheverolimusinterfereswiththegrowthandangiogenicactivityofrenalcellcarcinoma
AT deplacidosabino combinationofatolllikereceptor9agonistwitheverolimusinterfereswiththegrowthandangiogenicactivityofrenalcellcarcinoma
AT biancoroberto combinationofatolllikereceptor9agonistwitheverolimusinterfereswiththegrowthandangiogenicactivityofrenalcellcarcinoma

Ejemplares similares